Development and Validation of an Automated Image-Based Deep Learning Platform for Sarcopenia Assessment in Head and Neck Cancer.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 08 2023
Historique:
medline: 11 8 2023
pubmed: 10 8 2023
entrez: 10 8 2023
Statut: epublish

Résumé

Sarcopenia is an established prognostic factor in patients with head and neck squamous cell carcinoma (HNSCC); the quantification of sarcopenia assessed by imaging is typically achieved through the skeletal muscle index (SMI), which can be derived from cervical skeletal muscle segmentation and cross-sectional area. However, manual muscle segmentation is labor intensive, prone to interobserver variability, and impractical for large-scale clinical use. To develop and externally validate a fully automated image-based deep learning platform for cervical vertebral muscle segmentation and SMI calculation and evaluate associations with survival and treatment toxicity outcomes. For this prognostic study, a model development data set was curated from publicly available and deidentified data from patients with HNSCC treated at MD Anderson Cancer Center between January 1, 2003, and December 31, 2013. A total of 899 patients undergoing primary radiation for HNSCC with abdominal computed tomography scans and complete clinical information were selected. An external validation data set was retrospectively collected from patients undergoing primary radiation therapy between January 1, 1996, and December 31, 2013, at Brigham and Women's Hospital. The data analysis was performed between May 1, 2022, and March 31, 2023. C3 vertebral skeletal muscle segmentation during radiation therapy for HNSCC. Overall survival and treatment toxicity outcomes of HNSCC. The total patient cohort comprised 899 patients with HNSCC (median [range] age, 58 [24-90] years; 140 female [15.6%] and 755 male [84.0%]). Dice similarity coefficients for the validation set (n = 96) and internal test set (n = 48) were 0.90 (95% CI, 0.90-0.91) and 0.90 (95% CI, 0.89-0.91), respectively, with a mean 96.2% acceptable rate between 2 reviewers on external clinical testing (n = 377). Estimated cross-sectional area and SMI values were associated with manually annotated values (Pearson r = 0.99; P < .001) across data sets. On multivariable Cox proportional hazards regression, SMI-derived sarcopenia was associated with worse overall survival (hazard ratio, 2.05; 95% CI, 1.04-4.04; P = .04) and longer feeding tube duration (median [range], 162 [6-1477] vs 134 [15-1255] days; hazard ratio, 0.66; 95% CI, 0.48-0.89; P = .006) than no sarcopenia. This prognostic study's findings show external validation of a fully automated deep learning pipeline to accurately measure sarcopenia in HNSCC and an association with important disease outcomes. The pipeline could enable the integration of sarcopenia assessment into clinical decision making for individuals with HNSCC.

Identifiants

pubmed: 37561460
pii: 2808141
doi: 10.1001/jamanetworkopen.2023.28280
pmc: PMC10415962
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2328280

Subventions

Organisme : NIDCR NIH HHS
ID : F31 DE031502
Pays : United States
Organisme : NIDCR NIH HHS
ID : K08 DE030216
Pays : United States

Commentaires et corrections

Type : UpdateOf

Références

Eur Arch Otorhinolaryngol. 2019 Apr;276(4):1175-1182
pubmed: 30689037
Cancer Res Commun. 2023 Jun 29;3(6):1140-1151
pubmed: 37397861
Lancet Digit Health. 2022 Sep;4(9):e657-e666
pubmed: 36028289
JAMA Otolaryngol Head Neck Surg. 2019 Jul 1;145(7):647-654
pubmed: 31169874
Eur J Radiol. 2018 Dec;109:142-146
pubmed: 30527297
Injury. 2022 Nov;53 Suppl 3:S30-S41
pubmed: 35680433
Radiother Oncol. 2019 Aug;137:117-124
pubmed: 31085391
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Lancet Digit Health. 2023 Jun;5(6):e360-e369
pubmed: 37087370
Oral Oncol. 2017 Aug;71:26-33
pubmed: 28688687
Clin Nutr. 2020 Feb;39(2):501-509
pubmed: 30846324
Sci Data. 2022 Aug 2;9(1):470
pubmed: 35918336
Laryngoscope. 2021 Feb;131(2):333-341
pubmed: 32220072
Radiother Oncol. 2021 Apr;157:147-154
pubmed: 33545258
AJR Am J Roentgenol. 2022 Jan;218(1):124-131
pubmed: 34406056
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
JAMA Oncol. 2016 Jun 01;2(6):782-9
pubmed: 26891703
Br J Math Stat Psychol. 2008 May;61(Pt 1):29-48
pubmed: 18482474
Front Oncol. 2022 Jul 28;12:930432
pubmed: 35965493
J Am Med Dir Assoc. 2011 May;12(4):249-56
pubmed: 21527165
Acad Radiol. 2020 Mar;27(3):311-320
pubmed: 31126808
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Radiother Oncol. 2020 Jun;147:103-110
pubmed: 32251949
Eur Urol. 2015 Jun;67(6):1142-1151
pubmed: 25572824
Radiol Artif Intell. 2022 May 04;4(3):e210285
pubmed: 35652117
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Oral Oncol. 2016 Nov;62:28-33
pubmed: 27865369
J Acad Nutr Diet. 2020 Aug;120(8):1330-1347.e8
pubmed: 32711854
Head Neck. 2019 Nov;41(11):4000-4008
pubmed: 31472000
Cancers (Basel). 2019 Nov 25;11(12):
pubmed: 31769421
Eur J Cancer Care (Engl). 2021 Jan;30(1):e13343
pubmed: 33043532
Front Oncol. 2022 Feb 14;12:812159
pubmed: 35237517
Front Oncol. 2021 May 07;11:580806
pubmed: 34026597
Head Neck. 2022 Jan;44(1):189-200
pubmed: 34713519
Gerontology. 2014;60(4):294-305
pubmed: 24731978
BMC Geriatr. 2016 Oct 5;16(1):170
pubmed: 27716195
Int J Oral Maxillofac Surg. 2021 Sep;50(9):1195-1202
pubmed: 33414037
Head Neck. 2017 Jun;39(6):1226-1233
pubmed: 28323362
Ann Oncol. 2010 May;21 Suppl 5:v184-6
pubmed: 20555077
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):1-12
pubmed: 10758302

Auteurs

Zezhong Ye (Z)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Anurag Saraf (A)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Yashwanth Ravipati (Y)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Frank Hoebers (F)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands.

Paul J Catalano (PJ)

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Yining Zha (Y)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Anna Zapaishchykova (A)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Radiology and Nuclear Medicine, CARIM and GROW, Maastricht University, Maastricht, the Netherlands.

Jirapat Likitlersuang (J)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Christian Guthier (C)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Roy B Tishler (RB)

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Jonathan D Schoenfeld (JD)

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Danielle N Margalit (DN)

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Robert I Haddad (RI)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Raymond H Mak (RH)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Mohamed Naser (M)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Kareem A Wahid (KA)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jaakko Sahlsten (J)

Department of Computer Science, Aalto University School of Science, Espoo, Finland.

Joel Jaskari (J)

Department of Computer Science, Aalto University School of Science, Espoo, Finland.

Kimmo Kaski (K)

Department of Computer Science, Aalto University School of Science, Espoo, Finland.

Antti A Mäkitie (AA)

Department Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Clifton D Fuller (CD)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Hugo J W L Aerts (HJWL)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Radiology and Nuclear Medicine, CARIM and GROW, Maastricht University, Maastricht, the Netherlands.
Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Benjamin H Kann (BH)

Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH